CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Trial Details

NCT ID

NCT04603872

Phase

EARLY_PHASE1

Sponsor

Zhejiang University

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

• CD19/BCMA Targeted CAR T-cells and dasatinib
• CD19/BCMA Targeted CAR T-cells

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• Histologically confirmed diagnosis of CD19+ ALL, CD19+ NHL, or BCMA+ MM per the US National Comprehensive Cancer Network (NCCN) Clinical Practice G…
• Relapsed or refractory B cell hematological malignancies (meeting one of the following conditions):
• CR not achieved after standardized chemotherapy;
• CR achieved following the first induction, but CR duration is less than 12 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.